Schrodinger, Inc. Common Stock

Schrodinger trades with an extraordinary 24.52% short interest—nearly a quarter of floats held by bears—while RSI screams overbought at 74.5, creating a potent squeeze setup. The $1.1B biotech player lacks profitable earnings (no P/E available), meaning valuation rests entirely on pipeline promise rather than cash generation. This combination of extreme technical extension, elevated short pressure, and fundamental uncertainty suggests elevated volatility ahead; the stock sits between competing forces—momentum chasers versus fundamental skeptics—with little margin for disappointment in clinical progress.